Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:BDRX NASDAQ:KALA NASDAQ:KPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.12+0.5%$1.23$0.85▼$4.40$35.88M0.2130,934 shs6,695 shsBDRXBiodexa Pharmaceuticals$0.85+1.4%$1.07$0.78▼$24.75$31.06M1.172.07 million shs254,276 shsKALAKALA BIO$5.96$4.41$2.92▼$11.20$38.44M-1.8849,827 shs47,987 shsKPRXKiora Pharmaceuticals$3.14-0.3%$3.07$2.51▼$4.86$9.56M-0.66224,963 shs39,623 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+1.85%-1.46%+1.83%-7.81%-70.00%BDRXBiodexa Pharmaceuticals-4.53%-4.24%-19.23%-41.26%+83,999,900.00%KALAKALA BIO+8.96%-5.40%+37.33%+72.75%-23.79%KPRXKiora Pharmaceuticals+5.00%+6.06%+4.65%+12.90%-26.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari Therapeutics0.8853 of 5 stars0.03.00.00.01.93.30.0BDRXBiodexa Pharmaceuticals0.2059 of 5 stars0.03.00.00.02.00.00.0KALAKALA BIO3.9233 of 5 stars3.52.00.04.42.30.80.6KPRXKiora Pharmaceuticals3.1851 of 5 stars3.55.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/ABDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AKALAKALA BIO 3.00Buy$13.00118.12% UpsideKPRXKiora Pharmaceuticals 3.00Buy$10.00218.47% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, KALA, BDRX, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/A$0.29 per shareN/AKALAKALA BIO$3.89M9.88N/AN/A$2.02 per share2.95KPRXKiora PharmaceuticalsN/AN/A$1.30 per share2.42$8.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-213.59%-65.60%8/18/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AKALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)KPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)Latest KPRX, KALA, BDRX, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025KPRXKiora Pharmaceuticals-$0.58N/AN/AN/A$0.75 millionN/A8/5/2025Q2 2025KALAKALA BIO-$1.82N/AN/AN/AN/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.160.16BDRXBiodexa Pharmaceuticals0.011.751.75KALAKALA BIO3.191.991.99KPRXKiora PharmaceuticalsN/A5.145.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BDRXBiodexa Pharmaceuticals17.51%KALAKALA BIO24.61%KPRXKiora Pharmaceuticals76.97%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%BDRXBiodexa Pharmaceuticals0.34%KALAKALA BIO8.32%KPRXKiora Pharmaceuticals0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million19.92 millionNot OptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableKALAKALA BIO306.45 million5.92 millionNot OptionableKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableKPRX, KALA, BDRX, and AKTX HeadlinesRecent News About These CompaniesKiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should KnowJuly 16 at 1:01 PM | zacks.comKiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.8% Higher - What's Next?July 9, 2025 | americanbankingnews.comkiora pharmaceuticals reports results of annual shareholder meetingJune 6, 2025 | investing.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | finanznachrichten.deKiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | newsfilecorp.comNKiora Pharmaceuticals Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comKiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027May 9, 2025 | newsfilecorp.comNKiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative VitreoretinopathyMay 5, 2025 | finance.yahoo.comKiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | newsfilecorp.comNKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 25, 2025 | tipranks.comKiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027March 25, 2025 | newsfilecorp.comNKiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual MeetingMarch 12, 2025 | newsfilecorp.comNKiora Pharmaceuticals secures new patent for KIO-104February 13, 2025 | msn.comKiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104February 13, 2025 | newsfilecorp.comNKiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular EdemaFebruary 11, 2025 | newsfilecorp.comNWe Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be ConservativeNovember 15, 2024 | finance.yahoo.comKiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial PositionNovember 12, 2024 | markets.businessinsider.comKiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 StudiesNovember 8, 2024 | newsfilecorp.comNPositive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy RatingNovember 1, 2024 | markets.businessinsider.comKiora Pharmaceuticals Gains Approval for Phase 2 TrialOctober 29, 2024 | markets.businessinsider.comMedia Sentiment Over TimeKPRX, KALA, BDRX, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.12 +0.01 (+0.45%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Biodexa Pharmaceuticals NASDAQ:BDRX$0.85 +0.01 (+1.43%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.KALA BIO NASDAQ:KALA$5.96 0.00 (0.00%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Kiora Pharmaceuticals NASDAQ:KPRX$3.14 -0.01 (-0.32%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
